NCT01699152View on ClinicalTrials.gov

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

May 31, 2016

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

TG02 citrate

TG02 citrate capsules

Trial Locations (5)

30912

GRU, Augusta

37203

SCRI, Nashville

43210

OSU, Columbus

77030

MDACC, Houston

02215

DFCI, Boston

All Listed Sponsors
lead

Tragara Pharmaceuticals, Inc.

INDUSTRY

NCT01699152 - Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter